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Abstract
Background: A significant fraction of the more than 18 million scientific articles currently indexed in the PubMed database
are related to immune responses to various agents, including infectious microbes, autoantigens, allergens, transplants,
cancer antigens and others. The Immune Epitope Database (IEDB) is an online repository that catalogs immune epitope
reactivity data derived from articles listed in the National Library of Medicine PubMed database. The IEDB is maintained and
continually updated by monitoring PubMed for new, potentially relevant references.
Methodology: Herein we detail the classification of all epitope-specific literature in over 100 different immunological
domains representing Infectious Diseases and Microbes, Autoimmunity, Allergy, Transplantation and Cancer. The relative
number of references in each category reflects past and present areas of research on immune reactivities. In addition to
describing the overall landscape of data distribution, this particular characterization of the epitope reference data also
allows for the exploration of possible correlations with global disease morbidity and mortality data.
Conclusions/Significance: While in most cases diseases associated with high morbidity and mortality rates were amongst
the most studied, a number of high impact diseases such as dengue, Schistosoma, HSV-2, B. pertussis and Chlamydia
trachoma, were found to have very little coverage. The data analyzed in this fashion represents the first estimate of how
reported immunological data corresponds to disease-related morbidity and mortality, and confirms significant discrepancies
in the overall research foci versus disease burden, thus identifying important gaps to be pursued by future research. These
findings may also provide a justification for redirecting a portion of research funds into some of the underfunded, critical
disease areas.
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Introduction
More than 18 million scientific articles are currently indexed in
the PubMed database.
A significant number of these relate to epitopes associated with
immune responses to various agents, including infectious mi-
crobes, autoantigens, allergens, transplants, cancer antigens and
others. The relative number of references in each category reflects
the current and past research focus on immune reactivities. Here
we analyze the data from these different domains to evaluate
overall epitope data coverage therein, and highlight the strengths
and weakness in our overall knowledge base.
The Immune Epitope Database (IEDB) is an online repository
of manually curated data, which catalogs immune epitope
reactivity data [www.immuneepitope.org]. The PubMed database
is constantly queried for potentially relevant references. To
capture the highest possible fraction of references describing
immune epitope data, these queries are intentionally broad. To
date more than 21,000 references of potential interest (.1% of
PubMed) have been identified for inclusion into the IEDB. Their
potential relevance is determined first by an automated text
classifier based on the information contained within their abstract,
title and journal title [1], and then manually by subject matter
experts. The criteria for passing this initial selection process
require that i) the reference contains experimental data describing
adaptive immune responses, ii) the data is original (for example,
review papers and use of epitopes as a mere marker or tag are
excluded), and iii) the epitope molecular structure is described in
sufficient detail [2]. Following these preliminary determinations, a
systematic review of the paper is performed, and if the study is still
deemed to contain curatable information, the data are extracted,
entered into the database and the curated record then becomes
available to the public.
Results
A broad-net strategy to capture epitope-related
literature
Currently, four different immunological domains are recognized
and prioritized for curation within the IEDB. As first priority,
Infectious Diseases and Microbes have been targeted, followed by
Allergy, Autoimmunity and Transplantation. Accordingly, the
curation of all references from Allergy and Infectious Diseases is
nearly complete (.80% and 90%, respectively). In order to
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6948enhance the curation prioritization process, we recently further
categorized all potential references into six main immunological
domains, or classes. These classes include the four original
domains: Infectious Disease and Microbes (excluding HIV),
Allergy, Autoimmunity and Transplantation, plus HIV (including
SIV and related viruses) and Cancer. References containing
immune epitope data, but not pertinent to any of the main classes
were categorized as ‘‘Other’’. This detailed classification allows
not only for enhanced prioritization, but also enables a more
accurate/thorough description and accounting of the IEDB
reference data.
The relative number of references classified in each of these
main classes is shown in Figure 1. It can be seen that Infectious
Diseases and Microbes represent the majority of references,
accounting for 31% of the references. Together with HIV
references (,11%), Infectious Diseases therefore represent more
than 42% of the immune epitope literature.
Next, Autoimmunity and ‘‘Other’’ references make up nearly
20% each. Cancer references represent nearly 12% of the
references, and finally, the least references are available for the
Allergies and Transplantation classes (less than 5% each). Each
main class was next parsed in a finer set of categories.
A detailed breakdown of the pathogens associated with
Infectious Diseases/and Microbes references
Using the established NCBI taxonomy, eight major categories
were defined within the Infectious Diseases and Microbes class: 1)
negative strand RNA viruses, 2) positive strand RNA viruses,
3) retro-transcribing viruses [Retroviridae, Hepadnaviridae], 4)
double-stranded DNA (dsDNA) viruses, 5) Other viruses,
6) Actinobacteria and Proteobacteria 7) Other bacteria, and 8)
eukaryotic organisms. Each of these categories corresponds to
different phylogenetic groupings designed to encompass approx-
imately all related references, with the exception of the ‘‘Other
viruses’’ category, which contains approximately 109 references
(Figure 2a). Each category was further classified in several
subcategories (Table S1).
The overall greatest representation was from viral pathogens
(59.2%), followed by bacterial pathogens (22.4%) and parasites
(18.4%). Looking at the individual categories, the majority of
references within negative-strand RNA viruses, are derived from
influenza viruses (52%), followed by viruses within the Paramyx-
oviridae family (RSV, Measles, Mumps; 25.5%) [Table S1].
Within positive-strand RNA viruses, the hepatitis C virus (HCV)
subcategory accounts for about 34.1% of the references, followed
by Picornaviruses (poliovirus, coxsackievirus, foot and mouth
disease virus; 26.3%). The Flaviviridae (West Nile, yellow fever
virus and dengue virus) and Nidovirales (SARS and other
coronaviruses) families are less well represented, representing 8.5
and 13.2%, respectively. In the retro-transcribing virus category,
excluding Lentiviruses (HIV, SIV) which are separately classified
by another group in the HIV Los Alamos database [www.hiv.lanl.
gov], the delta retrovirus (HTLV) and hepatitis B virus (HBV)
represent the bulk of the category, with 22.1% and 53.5%,
respectively. In the category of dsDNA viruses, Herpesviridae are
by far the most represented. Specifically, there are 185, 208 and
233 references each for alpha, beta and gamma herpesviruses,
respectively, accounting for 57% of the category. Another 315
references are related to human papilloma virus (HPV). Finally,
relatively few (45) references are related to poxviruses.
Within the Actinobacteria/Proteobacteria category, references
related to Mycobacteria are by far the most numerous (39.6%),
followed by Enterobacteria (E.coli, Salmonella, Yersinia, Shigella
and Proteus). Fewer references are related to other classes
containing important human pathogens, such as bacteria in the
genera Vibrio, Haemophilus, Pseudomonas, Anaplasmas, Neisse-
ria and Bordetella. Likewise, in the category of Firmicutes/Other
Bacteria, well-represented categories include Listeria, Streptococci
and Clostridiales. References describing epitopes from Staphylo-
coccus, Chlamydia, Spirochaetes and other bacteria are less well
represented. Finally, in terms of parasitic eukaryotic organisms,
the most references by far are represented as relating to
Plasmodium [malaria] (48.1%); followed by Eukaryotic inverte-
brates such as Nematodes, Platyhelminthes, and Schistosomas
Figure 1. Distribution of references within main classes. The data represent the distribution of the 21,269 total potentially relevant references
by percentage (%) and total number within each main class.
doi:10.1371/journal.pone.0006948.g001
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this category, such as Entamoeba, Theliera and Babesia.
A classification of Autoimmunity references based on a
combination of associated disease and autoantigens
Epitope-specific references that were broadly related to
autoimmunity were classified in seven categories, based on the
specific type of autoimmune manifestations: 1) diabetes 2)
rheumatoid arthritis, 3) multiple sclerosis, 4) lupus, 5) myasthenia
gravis, 6) beta amyloid reactions/Alzheimer’s disease, and 7) other
autoimmune diseases. A pie chart representing the relative
distribution of these categories is shown in Figure 2b. As it can
be seen, multiple sclerosis is by far the most represented class, with
22.2% of the references, followed by the rheumatoid arthritis,
diabetes and lupus categories all represented by similar numbers of
references in the 10 to 17% range. Each of these categories was
further sub-categorized. These sub-categories were mostly orga-
nized on the basis of the protein or molecular structure recognized
by immune responses [Table S2].
Within the MS references, those relating to myelin oligoden-
drocyte glycoprotein (MOG), proteolipid protein (PLP) and myelin
basic protein (MBP) in aggregate represent 84% of the references,
and that references presenting data related to other target antigens
only encompass ,16% of the total. More specifically, three
subcategories relate to myelin basic protein (MBP), and these
collectively encompass ,68% of the MS related references.
References relating to the most well-characterized epitopes/
regions (MBP 78, MBP 1–9 and PLP 139–151) out-numbered
references describing all other epitopes derived from the same two
MS target antigens. We have chosen to classify these references
separately, and only a few representative references might be
curated in the IEDB for each epitope; references presenting largely
redundant data may be excluded or considered of lower priority.
A different picture emerges in the case of lupus-associated
references, where a myriad of different targets are reported. Here,
epitopes are derived from antigens of different chemical types
(proteins, lipids and DNA). With the exception of antiphospolipid
and anti-cardiolipin associated references, which represent ,44%
of the references, no other class of antigens appear to be greatly
over-represented in comparison to the others.
Within diabetes references, two subcategories encompass the
majority of the references, namely those related to proinsulin/insulin
and glutamic acid decarboxilase (GAD), respectively. Similarly, in
the case of rheumatoid arthritis, eight different reference subcate-
gories were defined, with most references belonging to collagen. The
next most represented subcategories were citrullinated epitopes, heat
shock proteins and rheumatoid factors/antibodies.
Finally in the broad class of ‘other’ autoimmune references, nine
main subcategories were defined ranging from reactions against
reproductive antigens (investigated as potential contraceptive
measures), anti-interferon and anti-von Willebrand factor reac-
tions (mostly associated with reactivity resulting from treatment
with protein therapeutics) and organ-specific autoimmune man-
ifestations (thyroid, liver, and uveitis). This class constitutes a large
percentage of the total autoimmune class, representing some 1248
references.
The Classification of Allergy references
Allergy references were classified in 3 main categories based on
the source of the allergen itself: plants (288 references), animals
Figure 2. Distribution of Main Infectious Disease Categories. The various pie charts represent the percentage (%) and total number of
references (in parentheses) of different categories within each main class. A) Infectious Disease and Microbes (non-HIV) B) Autoimmunity C) AllergyD )
Alloantigens and Transplantation.
doi:10.1371/journal.pone.0006948.g002
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representing the relative distribution of these categories is shown in
Figure 2c. Each of these categories was further classified in
subcategories [Table S3].
Within the Plant category, we further distinguish eight main
subcategories. Approximately one quarter of these references are
related to gluten and celiac disease.
The second most populated subcategories are those related to
Betulaceae (the birch family), Cupressaceae (the cypress and cedar
family) and Poaceae (mostly timothy grass). Less frequently
populated are the subcategories corresponding to latex and to
the Fabaceae family (soybean and peas), as well as ‘other trees’ and
‘other flowering plants.’
The animal and fungi category is further broken down in
various subcategories, corresponding to allergies to arachnids
(mites and ticks) 29.5%, and insects 18.4%, and fungi 12%. A
significant number of references are also identified corresponding
to allergens derived from vertebrates, such as animal dander or
food products (i.e. milk). Here, mammals and birds account for
26.7% and 6%, respectively, of the references in the Eukaryote
(Non-plant) category.
Finally, within the ‘other allergens’ category, most references
relate to small, non-peptidic experimental allergens involved in
hypersensitivity reactions and/or commonly utilized as model
small molecule allergens (haptens). Of these, nearly half involve
dinitrophenol (DNP) and related molecules, and a much smaller
fraction relates to metals (nickel, beryllium and others). Other
haptens encompass the remaining 40% or so of the references.
The classification of Alloantigen and Transplantation
references
The main class of Transplantation/allorecognition represents
the smallest class and a fairly heterogeneous set of references. A
relative large fraction of these references is related to galactose
(15.1%), an important determinant recognized by rejection-
associated antibodies. Other related categories included xeno-
tranplantation (10.1%) and blood groups (8%). Also very
prominent is the category of references related to MHC molecules
(18.1%), which represent important targets, either as a whole
protein, or as a source of allorecognized peptides. Other
allopeptides include the minor histocompatibility antigen (HY
protein) category (4.3%), generic allopeptides (20%), and minor
antigens (9.7%). Finally, two additional categories represent
epitopes associated with specific disease settings such as thrombo-
cytopenia and graft-versus-host disease (graft rejection). A pie
chart representing the relative distribution of these categories is
shown in Figure 2d and Table S4 provides a breakdown of these
categories by number of references.
The ‘other’ references
To avoid duplication of ongoing efforts at the HIV Los Alamos
database [www.hiv.lanl.gov], references related to HIV, SIV and
other Lentiviruses are presently not included within the scope of the
IEDB. Likewise, cancer references involving specific immune epitopes
are not currently considered within NIAID’s priority, and accordingly,
their categorization is not described herein. The final main class,
‘‘Other,’’ was designed as a catchall for those references not
conforming to any of the above organism- or disease-based groupings.
However, perusal of the references within this class helps complete the
picture of molecular targets related to adaptive immune responses.
These 3,765 references were further sub-dived in eight
categories (Table 1). The most numerous categories were related
to non-disease-related, non-peptidic antigens, such as the DNP
hapten (7.8%), carbohydrate epitopes (2.5%), gangliosides (5.1%),
and other small molecular/haptens (24%). References related to
the definition of epitopes recognized by monoclonal antibodies
(20.8%), and by other non-monoclonal B cell responses (8.8%) are
also rather numerous. Additional categories capture model
antigens, like cytochrome C (Cyt C), hen egg white lysozyme
(HEL) and class II-associated invariant chain peptides (CLIP). A
large number of papers also exist in the scientific literature relating
to ovalbumin (OVA) epitopes, specifically OVA 257–264
(SIINFEKL) and OVA 323–339 (ISQAVHAAHAEINEAGR).
Representative references for these two epitopes have been, or are
in the process of being captured. In most other instances these
epitopes are utilized as ‘tags’ and thereby are likely to be excluded
in the database. Finally, other categories in this class relate to
naturally processed ligands eluted from MHC molecules, (5.8%),
epitopes defined by X-ray crystallography, NMR structures
(3.3%), and definition of MHC binding motifs (4.6%).
Time course of reference deposition
Having completed the categorization of all references, we
investigated the time course of publication. Figure 3a shows the
rate of new publication describing epitope data as appearing in the
scientific literature between 1960 and the current year. While a
negligible number of publications were observed between 1960 to
the mid 1970’s, a sudden jump in the number of publications
occurred thereafter. This increase in epitope-related literature is
likely related to the discovery and utilization of monoclonal
antibodies. A further remarkable jump in publications occurs in
the mid to late 1980s’, probably related to the demonstration that
Table 1. Classification of ‘‘Other’’ References.
Category
# of
References
%o f
Total
Non-Peptidic Antigens
DNP, TNFB, TNP, TNCB 293 7.8%
Other Haptens 905 24.0%
Galactose (Sugars) 94 2.5%
Gangliosides 192 5.1%
Total 1484 39.4%
Model Antigens
Class II-associated Invariant Chain
Peptides
28 0.7%
Lysozyme (HEL) 200 5.3%
Myoglobin 58 1.5%
Cytochrome C, Other Cytochromes 128 3.4%
Analog, Antagonist 62 1.6%
Total 476 12.7%
Monoclonal Antibodies 783 20.8%
B Cell Other 331 8.8%
T Cell Other 175 4.6%
Motifs 172 4.6%
Structure 126 3.3%
Naturally Processed 218 5.8%
Total 1805 47.9%
Grand Total 3,765 100.0%
Each subcategory describes the number of references, as well as the percentage
with regard to the absolute total number of ‘‘Other’’ references.
doi:10.1371/journal.pone.0006948.t001
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different class. HIV data are shown separately from infectious disease to avoid duplication of ongoing efforts at the HIV Los Alamos database [www.
hiv.lanl.gov]. B) The number of epitope-related publications is plotted against year of publication for each different category within the ‘‘Other’’ class.
doi:10.1371/journal.pone.0006948.g003
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T cells. Epitope references for HIV increased steadily starting in
the late 1980s, reaching a peak in the early 90s that leveled off and
remained fairly constant thereafter.
In general, all categories followa similar trend,with the exception
of the ‘other’ class, which appears to start accumulating references
sooner than the others, but also appears to level off and even
decrease in rate in more recent times. To investigate the reason for
this profile, we plotted the rate of publication of each of the
subcategory, as shown in Figure 3b. This analysis revealed a rather
complex picture. It was found that references in PubMed relating to
non-peptidic antigens were responsible for the initial jump during
the mid-1970s, but declined steadily after peaking in the mid 1980s.
References relating to model protein antigens start to appear in the
early 80s, peak in 1999 and decline sharply thereafter. Likewise,
references related to definition of epitopes recognized by polyclonal
antibodies peak in the early 1990s and then decline, in
concomitance with the rise, also in the 90s, of references describing
epitopes recognized by monoclonal antibodies. Likewise, references
relating to definition of MHC motifs and elution of naturally
processed ligands, peak in the mid 90s and decline thereafter.
Correlation with societal impact
The categorization of immune epitope data presented herein
relates to domains such as Infectious Diseases and Microbes,
Autoimmunity, Allergy and Transplantation. It may therefore be
taken as representative of the degree to which the molecular
targets associated with these diseases have been scrutinized and
defined. An immune epitope is defined by the IEDB as the
molecular structure interacting with receptors of the immune
system (T cell and B cell/antibody). Accordingly this definition
excludes, for example, structures involved in lectin-carbohydrate
interactions, or structures recognized by receptors involved in
innate immunity, such as NK cells. Immune epitopes are defined
in the literature with varying level of resolution. In some cases the
minimal/optimal residues of a T or B cell determinant are exactly
defined, while in other cases only certain key components are
mapped. Finally, in certain instances broad regions are pinpointed
as containing the epitope, but the exact boundaries and
components are not defined. No structures .50aa are considered
for inclusion in the IEDB. Because it is difficult to adequately
compare the societal impact (i.e. disease burden in morbidity and
mortality) of vastly different diseases categories such as Allergies,
Cancer, Autoimmunity or Infectious Diseases, we have elected to
investigate the overall impact of disease burden within only the
infectious and autoimmune disease classes. For this purpose, we
examined global morbidity (prevalence) and mortality data for a
representative list of pathogen/diseases, and then compared these
data to the number of references in each category.
A total of thirty infectious diseases were selected based on the
most prevalent disease categories for which sound epidemiological
data existed. Table 2 shows the ranking of each pathogen/disease
according to the total number of immune epitope references and
the estimated morbidity (prevalence) and mortality for each. The
ten pathogens associated with the most references are highlighted
in gray; the numbers in bold highlight the top ten pathogens/
diseases with respect to prevalence and mortality. The ranking of
disease by prevalence or mortality is also indicated in parentheses
(1–10). The top ten diseases by overall reference abundance are
HIV/AIDS, influenza, Malaria, HCV, HBV, HPV, TB, group A
Streptococcus, Measles and RSV.
In general, the majority of pathogens listed in the top ten most
prevalent in mortality have more than 100 references each, and
represents diseases responsible for morbidity in hundreds of
millions of people per year. While it is perhaps not surprising that
the epitope reference coverage would be high for prominent
infectious diseases [3], the length of the list of diseases for which
coverage was poor (,80 references) is surprising, as it includes five
very high impact diseases (dengue, Schistosoma, HSV-2, B.
pertussis and Chlamydia trachoma). Indeed, B. pertussis stands out
prominently, with some 60 million people infected per year and an
estimated 400,000 deaths, and a mere 16 references.
Figure 4 shows the coverage for autoimmune diseases described
by the immune epitope data. Interestingly, it seems that type I
diabetes and RA, despite being associated with higher morbidity
and/or mortality as compared to MS and lupus, are actually
associated with relatively lower numbers of references. It would
thus appear that a relative imbalance of epitope knowledge might
also exist in the Autoimmunity class, when analyzed in the context
of disease prevalence.
In the past [4], we have also investigated overall epitope
coverage at the genomic level by calculating the total number of
Table 2. Ranking of Epitope References by Infectious Disease
Burden.
Rank Pathogen/Disease Refs Cases Deaths
1 HIV/AIDS 2,297 33,000,000
(1) 2,000,000
2 Influenza 548
(1) 600,000,000
(8) 375,000
3 Malaria 483
(5) 247,000,000
(4) 881,000
4 Hepatitis C 356
(6) 170,000,000 54,000
5 Hepatitis B 323
(3) 350,000,000
(3) 900,000
6 HPV (Cervical Cancer) 282 500,000
(9) 240,000
7 TB (Active) 264 14,400,000
(2) 1,700,000
8 GAS 178 18,000,000
(5) 500,000
9 Measles 93 279,000 197,000
10 RSV 92
(9) 64,000,000 160,000
11 Typhoid fever (S. typhi) 86 19,000,000
(10) 216,000
12 Schistosoma 74
(4) 261,000,000 41,000
13 Dengue 68
(8) 100,000,000 22,000
14 Polio 59 1,600 NA
15 T. cruzi 58 6,500,000 52,000
16 C. trachomatis 57
(7) 140,000,000 9,000
17 N. meningitidis 55 1,700,000 170,000
18 Leprosy 54 212,000 5,400
19 Leishmania 51 12,000,000 47,000
20 Haemophilus (HiB) 44 3,000,000
(7) 386,000
21 Rabies 44 10,000,000 55,000
22 HSV-2 38
(2) 536,000,000 NA
23 V. cholerae 33 3,000,000 120,000
24 Rubella 31 836,000 20,000
25 West Nile 21 29,000 1,070
26 B. pertussis 16
(10) 60,000,000
(6) 400,000
27 Yellow Fever 16 200,000 30,000
28 N. gonorrhoeae 15 52,000,000 1,000
29 Ebola 13 2,000 1,200
30 Mumps 7 3,000,000 300
Diseases are ranked (1–30) according to the number of immune epitope
references (related to infectious disease) identified in PubMed. The number in
parentheses indicates their respective ranking (1–10).
doi:10.1371/journal.pone.0006948.t002
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the genome by antigen targeted for epitope identification.
Applying this approach to the current analysis, we calculated
coverage for high relevance/low reference coverage pathogens
and compare these to high profile pathogens (Table 3). In the
majority of cases, pathogens well-represented in the literature have
greater epitope coverage, whereas those less well-represented have
lower epitope coverage. While the epitope coverage was greater
for high profile pathogens like TB and Malaria, the actual
percentage itself was rather low (ex. 7% for TB and 0.9% for
Malaria). Furthermore, high overall coverage does not necessarily
translate in well-balanced coverage. In many cases, the majority of
the identified epitopes come from very few antigens. This
phenomenon was observed and previously discussed in detail for
high profile pathogens such as P. falciparum, TB and influenza [4–
6]. These results further emphasize how the current epitope
literature is far from complete and how numerous gaps and
opportunities for further investigation still exist.
Discussion
The data presented herein for the first time allows for a glimpse
of the balance of references contained in the scientific literature,
related to epitope data and to all associated immunological
domains, including Infectious Diseases and Microbes, Autoimmu-
nity, Allergy, Transplantation and Cancer. Several conclusions
emerged from the analysis of the data gathered so far.
First, it is of interest to note the relative distribution of the
references among the domains, or classes. By far the majority of
references are related to Infectious Diseases and Autoimmunity.
Cancer is a distant third, and relatively fewer references are
available for Transplantation and allergies. It is unclear at this
stage whether this reflects a differential focus of the scientific
community, or inherent difficulties in defining the molecular
targets (epitopes) recognized by adaptive immune responses in
those settings. Interestingly, within the Infectious Disease class, we
found that references representing viral pathogens outnumber
bacterial and parasitic pathogens by about 3 to 1. This is likely due
to biological factors relating to genome size and/or antigenic
complexity. The autoimmune class is dominated by MS references
and, not surprisingly, the Allergy class shows a majority of
references defining plant allergens. References related to Trans-
plantation are mostly focused on allo-antigens/major histocom-
patibility complexes.
In addition to describing the overall distribution of data within
the six classes, this characterization of the epitope reference data
Figure 4. Morbidity Data for Autoimmune Diseases. Prevalence data for Type I diabetes is an extrapolation from total diabetes cases. Type I
diabetes represents only 10% of the total, which was reported as being 180,000,000 by the WHO.
doi:10.1371/journal.pone.0006948.g004
Table 3. Epitope Coverage.
Pathogen
Coverage in
Literature
Number of Proteins
with Defined Epitopes
Total Number of ORFs/
Expressed Proteins Percent (%)
TB HIGH 270 3,900 7
B. pertussis LOW 6 3,800 0.2
Malaria HIGH 46 5,000 0.9
S. mansoni LOW 15 12,880 0.1
Overall epitope coverage was assessed by comparing the coverage in the literature (total number of references), which was defined as high or low, and the precentage
of the genome (or total ORFs) represented by reported epitopes to date.
doi:10.1371/journal.pone.0006948.t003
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morbidity and mortality. Here, we investigated the relationship
between epitope coverage and overall disease burden by
comparing the top ten pathogens/diseases in terms of the total
number of references with the total number of cases and deaths
per year worldwide. This analysis showed that while most of the
high impact infectious diseases (in terms of prevalence and deaths)
were well-represented in the top ten, several very significant
diseases were represented by far fewer references, thus highlighting
a significant imbalance in the coverage. Examples of these high
relevance/low coverage infectious diseases are dengue, Schistoso-
ma, HSV-2, B. pertussis and Chlamydia trachoma. Similar observa-
tions were made for diseases within the autoimmune domain,
where the relatively lower impact diseases MS and lupus have
much greater epitope coverage than type 1 diabetes and RA.
These gaps are even more significant in light of our recent findings
following in-depth meta-analyses of some of the most well studied
diseases, such as influenza, TB and malaria [4–7], which revealed
significant gaps and imbalances within the immunological
knowledge associated with each of these pathogens.
A sub-analysis of several representative infectious diseases
undertaken to examine epitope coverage at the genomic level
showed similar results. In the majority of cases, pathogens well-
represented in the literature had greater epitope coverage, as
measured by the number of ORFs targeted for epitope
identification, whereas those less well-represented had lower
epitope coverage. However, while the epitope coverage was
greater for high profile pathogens like TB and Malaria, the actual
percentage itself was rather low. This overall lack of coverage for
these pathogens is likely due to a combination of factors, including
genome size and organism complexity. Indeed, the genome of M.
tuberculosis is ,4,000 ORFs, and the etiological agent of malaria, P.
falciparum, has an even larger genome and a complex 3-stage life
cycle. In addition, we found that good coverage did not necessarily
translate in well-balanced coverage, as in many instances, the bulk
of epitope identification focuses on just a few of the total antigens.
This observation has been made previously by our group, the best
example of which is malaria. Here we found that the vast majority
of epitope identification was focused on the circumsporozoite
surface protein (CSP), despite the 5,000+ ORFs in existence [6].
These results have relevance to the ongoing debate as to whether
the direction of biomedical research accurately reflects the reality of
the global disease burden [8]. A recent report [9] analyzing the
global burden of major infectious diseases indicated that R&D
funders have focused overwhelmingly on TB, Malaria and HIV/
AIDS, while other diseases with an even bigger burden get little
R&D attention. Indeed, numerous studies have already highlighted
thistrend[10,11].Accordingto anotherreportfromaninternational
research foundation [12], less than 10% of the world’s research
budget is spent on conditions that account for 90% of global disease.
Our data represents the first estimate of how knowledge in terms of
immunological data, rather than R&D funding corresponds to
disease morbidity and mortality, and confirms significant discrep-
ancies in the overall research focus versus disease burden, thus
identifying important gaps to be pursued by future research.
One important issue that became apparent upon embarking in
the classification of the overall ‘‘universe’’ of epitope-specific
references is that not all classification schema are applicable to the
various broad domains of immunological literature. In the case of
infectious diseases, we utilized the NCBI taxonomy as a guide in
the categorization.
However, in the case of autoimmunity, the classification is not
related to the organism from which the epitope is derived, but
rather from a broad classification of the associated autoimmune
disease manifestation. Furthermore, within each autoimmune
category, sub-categories were mostly organized on the basis of the
protein or molecule recognized.
This approach was taken to reflect the classification utilized by
most scientists operating in this field. The classification of allergy
references also required development of a similar approach,
because a classification based on the organism source of the
allergen would not conform to the established classification in use
in the allergy community. Here we were able to rely on the
backbone of the newly formalized immunological ontology to help
establish meaningful categories and sub-categories.
Finally, we would like to point out how the current data is by
necessity preliminary, as the accuracy of the classification of the
references is dependent on the stage of the curation process. For
example, in our experience about 30% of the references deemed
potentially acceptable on the basis of the abstract, are eventually
disqualified from curation because they fail to meet all inclusion
criteria. Thus approximately 70% of targeted references become
incorporated into the database. We would also like to underscore
that the work presented herein is tightly linked to other efforts
currently ongoing with the IEDB. Specifically, the present work
benefits from the development of formal ontologies and classification
of immune epitope data [13], and at the same time informs further
development of ontologies and controlled vocabularies, as new
reference categories are curated. Most importantly, the current work
has crucially relied on the development of automated text classifiers
[1], and in turn the present data can be utilized to further develop
new methods of automated text classification and characterization.
Materials and Methods
Worldwide morbidity and mortality figures were obtained, in
large part, from the WHO using their publically available data.
The WHO draws on a wide range of data sources to quantify
global and regional effects of diseases, the details of which are not
discussed here, however are available on their websites [Tables S5
and S6] (www.who.int). When statistics were not available through
the WHO, we used the peer-reviewed literature and/or personal
communication with experts in the respective fields. Further
validation was sought for these figures by contacting subject matter
experts (SMEs) to confirm the accuracy of estimates and
timeframes. Because morbidity and mortality data for individual
pathogens/diseases are acquired at different yearly intervals, data
derived from a single year could not be determined for all of the
pathogens included herein. The majority of the figures were
available for years 2004–2008, however, some figures were older
than 2004 and have been noted. Accurate and reliable burden of
disease estimates are currently difficult to assess as a result of
inconsistent data collection and/or reporting, especially in the
developing world. Therefore, the majority of the data shown
presented herein are likely underestimates. The majority of the
prevalence data represents case estimates by the WHO, unless
otherwise noted as actual reported cases.
To accomplish this sub-analysis, we first assembled a consoli-
dated list of 30 pathogens to target from all the infectious disease
categories described in Table 1. These were selected based on the
most prevalent disease categories for which sound epidemiological
data existed. For example, within the broader categories such as
single stranded, positive sense RNA viruses, we selected prominent
pathogens such as measles virus, RSV, Mumps, rabies virus, Ebola
virus and all influenza viruses as representative of the group.
Preliminary prevalence and mortality figures were then assigned to
each pathogen using the WHO web page (WHO fact sheets). In
order to verify that our data corresponds with what is currently
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experts (SME) was generated using the ISI web of knowledge site
[apps.isiknowledge.com]. Under the Web of Science tab, the terms
‘‘morbidity or prevalence or mortality and disease x’’ were applied
in order to flag the top 5 experts within each disease-specific field
based on their total number of publications. Subject matter experts
were then formally contacted by email to seek independent
validation of the preliminary figures. Prevalence and mortality
numbers were then adjusted, if warranted, to those provided by
the SMEs. On average, three authors were emailed for each
disease in order to obtain validation. Diseases, for which reliable
figures could not be found and/or were not available through the
SMEs, were excluded from this part of the analysis.
Supporting Information
Table S1 This represents a summary of each major infectious
disease category, excluding HIV, showing subtype designations to
the specificity of the source organism’s genus. There are 6,567
infectious disease references, which are distributed across the main
infectious disease categories. The percentage column indicates
each category as a percent of the total amount of infectious disease
references.
Found at: doi:10.1371/journal.pone.0006948.s001 (0.09 MB
DOC)
Table S2 This represents a summary of the various autoimmune
main categories, as well as their specific subcategory designations.
These subcategories were organized on the basis of the actual
protein or molecular structure recognized by immune responses.
The percentage column indicates each category as a percent of the
total amount of autoimmune references.
Found at: doi:10.1371/journal.pone.0006948.s002 (0.08 MB
DOC)
Table S3 There are three main allergy categories and these were
further classified into subcategories. The main plants category
contains trees, plants and grasses. The non-plant eukaryotes
contain insects, mammals, birds, invertebrates and fungi. The
other allergens mainly consist of low molecular weight, non-
peptidic chemicals and haptens, as well as metals. The percentage
column indicates each category as a percent of the total amount of
allergy references.
Found at: doi:10.1371/journal.pone.0006948.s003 (0.05 MB
DOC)
Table S4 Table S4 describes the breakdown of the various
alloantigen/transplant subcategories. There are a total of 701
transplant-related journal publications, constituting the lowest
represented class. Each subcategory is presented as a percentage of
the total.
Found at: doi:10.1371/journal.pone.0006948.s004 (0.03 MB
DOC)
Table S5 Worldwide morbidity and mortality figures were
obtained, in large part, from the WHO using their publically
available data. The WHO draws on a wide range of data sources
to quantify global and regional effects of diseases, the details of
which are not discussed here, however are available on their
websites. When statistics were not available through the WHO, we
used the peer-reviewed literature and/or personal communication
with experts in the respective fields. Morbidity and mortality data
for individual pathogens/diseases are acquired at different yearly
intervals, data derived from a single year could not be determined
for all of the pathogens included herein. The majority of the
figures were available for years 2004–2008, however, some figures
were older than 2004 and have been noted.
Found at: doi:10.1371/journal.pone.0006948.s005 (0.06 MB
DOC)
Table S6 Worldwide morbidity and mortality figures were
obtained, in large part, from the WHO using their publically
available data. The WHO draws on a wide range of data sources
to quantify global and regional effects of diseases, the details of
which are not discussed here, however are available on their
websites. When statistics were not available through the WHO, we
used the peer-reviewed literature and/or personal communication
with experts in the respective fields. Morbidity and mortality data
for individual pathogens/diseases are acquired at different yearly
intervals, data derived from a single year could not be determined
for all of the pathogens included herein. The majority of the
figures were available for years 2004–2008, however, some figures
were older than 2004 and have been noted.
Found at: doi:10.1371/journal.pone.0006948.s006 (0.04 MB
DOC)
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